Damora Therapeutics, Inc. Common Stock’s (DMRA) Outperform Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research report released on Tuesday,Benzinga reports. The firm currently has a $40.00 price objective on the stock.

A number of other analysts have also weighed in on the stock. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Finally, Guggenheim upped their target price on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 4.9%

Damora Therapeutics, Inc. Common Stock stock opened at $20.23 on Tuesday. Damora Therapeutics, Inc. Common Stock has a 12-month low of $3.50 and a 12-month high of $38.33. The business’s 50-day moving average price is $27.58 and its two-hundred day moving average price is $26.11. The stock has a market cap of $1.25 billion, a PE ratio of -6.00 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. As a group, analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Insider Buying and Selling at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett acquired 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction that occurred on Friday, September 25th. The shares were bought at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares in the company, valued at $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 0.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Braidwell LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at approximately $42,146,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth $7,398,000. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth $303,000. Finally, Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth $260,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.